NYSE:MED Medifast (MED) Stock Price, News & Analysis $10.48 +0.28 (+2.72%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$10.45 -0.03 (-0.26%) As of 06/26/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medifast Stock (NYSE:MED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medifast alerts:Sign Up Key Stats Today's Range$10.04▼$10.5950-Day Range$10.16▼$13.1452-Week Range$9.22▼$15.46Volume1.59 million shsAverage Volume212,961 shsMarket Capitalization$116.50 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingReduce Company Overview Medifast, Inc. (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey. Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions. The company went public in 2001 and has since expanded its operations beyond the United States, serving customers in both the U.S. and Canada. Its offerings are distributed through a combination of e-commerce platforms and regional distribution centers, enabling efficient delivery of products to end users and reinforcing Medifast’s direct‐to‐consumer business model. Under the leadership of President and Chief Executive Officer Daniel Chard, Medifast continues to invest in product innovation, digital tools and community building to strengthen customer engagement and retention. The company’s management team emphasizes evidence‐based program development and high standards of quality control, reflecting its commitment to clinical rigor and long‐term client success. With a focus on metabolic health and sustainable lifestyle transformation, Medifast aims to maintain its position as a leader in the weight‐management industry.AI Generated. May Contain Errors. Read More Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 39% of companies evaluated by MarketBeat, and ranked 104th out of 150 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingReduce Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMedifast has a consensus price target of $12.00, representing about 14.5% upside from its current price of $10.48.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Medifast are expected to grow in the coming year, from ($1.97) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.13% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 15.34, which indicates bearish sentiment.Change versus previous monthShort interest in Medifast has recently decreased by 0.91%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. News and Social Media1.9 / 5News SentimentN/A News SentimentMedifast has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Consumer Staples companies.Search Interest2 people have searched for MED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $62,950.00 in company stock, which represents 0.0540% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $62,950.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.70% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MED Stock News HeadlinesMetabolic Health After 40: What Perimenopause and Menopause Mean for Weight ManagementJune 11, 2026 | globenewswire.comWhat Science-Backed Subscription Health Programs Measure DifferentlyJune 11, 2026 | globenewswire.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.June 27 at 1:00 AM | Weiss Ratings (Ad)Medifast Announces Chief Legal Officer Resignation and TransitionJune 1, 2026 | tipranks.comMedifast Taps Johnson to Succeed Chard as CEOMay 26, 2026 | marketwatch.comMedifast Announces New CEO and Leadership TransitionMay 26, 2026 | tipranks.comMedifast Confirms Appointment of Nicholas Johnson as Chief Executive OfficerMay 26, 2026 | businesswire.comWeight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term OutcomesMay 21, 2026 | globenewswire.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $10.66 at the beginning of the year. Since then, MED shares have decreased by 1.7% and is now trading at $10.4770. How were Medifast's earnings last quarter? Medifast Inc (NYSE:MED) released its quarterly earnings results on Monday, May, 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.36. The specialty retailer earned $76.04 million during the quarter, compared to analysts' expectations of $69.20 million. Medifast had a negative net margin of 5.78% and a negative trailing twelve-month return on equity of 4.80%. Read the conference call transcript. Who are Medifast's major shareholders? Medifast's top institutional investors include Renaissance Technologies LLC (6.96%), Dimensional Fund Advisors LP (3.28%), Lido Advisors LLC (1.65%) and Bank of America Corp DE (0.80%). Insiders that own company stock include Scott Schlackman, Daniel R Chard, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings5/04/2026Today6/27/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 MED's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry FOOD - MISC/DIVERSIFIED Sub-IndustryPersonal Products Current SymbolNYSE:MED CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees870Year Founded1981Price Target and Rating Average Price Target for Medifast$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+14.5%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.67 million Net Margins-5.78% Pretax Margin-2.34% Return on Equity-4.80% Return on Assets-3.83% Debt Debt-to-Equity RatioN/A Current Ratio4.80 Quick Ratio4.30 Sales & Book Value Annual Sales$385.79 million Price / Sales0.30 Cash Flow$0.43 per share Price / Cash Flow24.58 Book Value$18.10 per share Price / Book0.58Miscellaneous Outstanding Shares11,120,000Free Float10,708,000Market Cap$116.50 million OptionableOptionable Beta0.62 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NYSE:MED) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
